ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).

Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT trial (NCT04286438; SFJ Pharmaceuticals, Inc.). REVERSE-IT investigated the reversal of the antiplatelet effects of ticagrelor with an intravenous infusion of bentracimab (PB2452) in patients with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure. Patients were enrolled from approximately 200 centres in North America, Europe, and Asia-Pacific regions, including mainland China.

Findings showed that in patients undergoing surgery with major bleeding, bentracimab significantly restored platelet function as measured by PRU. Hemostasis was effective in the majority of cases, and no serious allergic, thrombotic or other events were related to the drug as per the adjudicators.

Interview Questions:

1. What is the importance behind the REVERSE-IT trial?

2. What was the study design and patient population?

3. What were the key findings, and how can these findings be used to identify patients who would benefit most from bentracimab?

4. What are the unanswered questions?

Recorded on-site at ACC in Chicago, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.